ClinicalTrials.gg
CompletedNCT02195700ARM-TDUpdated Nov 9, 2021Results posted

Aim to Reduce Movements in Tardive Dyskinesia

A Phase 2/3 interventional study of SD-809 and Placebo in Tardive Dyskinesia, sponsored by Auspex Pharmaceuticals, Inc.. Completed at 41 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Auspex Pharmaceuticals, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Tardive Dyskinesia with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Tardive Dyskinesia · United States.

Enrollment
9th of 27
117 · median 89
Started
2014
with 4 others
Phase 2/3
Only one
of the 31
Registered
11th of 31
by date
Lead sponsor
3 of 31
Auspex Pharmaceuticals, Inc.

Among the 31 studies in Tardive Dyskinesia with a site in United States, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2014, is the only one in phase 2/3, and was the 11th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

6 of the 31 studies in Tardive Dyskinesia with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Tardive Dyskinesia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

03

Conditions studied

  • Tardive Dyskinesia

Keywords

  • Dyskinesias
  • Movement Disorders
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Neurologic Manifestations
  • Signs and Symptoms
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of using a dopamine receptor antagonist for at least 3 months
  • Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening
  • Subjects with underlying psychiatric diagnosis are stable and have no change in psychoactive medications
  • Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months
  • History of being compliant with prescribed medications
  • Able to swallow study drug whole
  • Be in good general health and is expected to attend all study visits and complete study assessments
  • Female subjects must not be pregnant and agree to an acceptable method of

Exclusion criteria

Exclusion Criteria:

  • Currently receiving medication for the treatment of tardive dyskinesia
  • Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias
  • Have a serious untreated or undertreated psychiatric illness
  • Have recent history or presence of violent behavior
  • Have unstable or serious medical illness
  • Have evidence of hepatic impairment
  • Have evidence of renal impairment
  • Have known allergy to any component of SD-809 or tetrabenazine
  • Has participated in an drug or device trial and received study drug within 30 days
  • Have acknowledged use of illicit drugs
  • Have a history of alcohol or substance abuse in the previous 12 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    SD-809

    SD-809 tablets taken twice daily for 12 weeks.

    Drug: SD-809

  • Placebo comparator
    Sugar Pill

    Placebo tablets taken twice daily for 12 weeks.

    Drug: Placebo

Interventions

  • DrugSD-809

    SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.

    Also known as: deutetrabenazine, AUSTEDO®

  • DrugPlacebo

    Placebo tablets taken twice daily for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis

    AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point, treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. An unstructured covariance model was used.

    Time frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12

Secondary outcomes

  1. Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)

    The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.

    Time frame: Week 12

  2. Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)

    The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.

    Time frame: Week 12

  3. Change From Baseline to Week 12 in the Modified Craniocervical Dystonia Questionnaire (CDQ-24)

    The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the CDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 (no impairment) to 96 (severe impairment). Negative change from baseline scores indicate improvement.

    Time frame: Day 0 (Baseline), Week 12 with last observation carried forward

  4. Participants With Adverse Events for the Overall Treatment Period

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Time frame: Day 1 to Week 12

  5. Percentage Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis

    AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative percent change from baseline score indicates improvement. The MMRM model includes fixed effects for treatment, time point (weeks 2, 4, 6, 9, 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. Patient is a random effect.

    Time frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12

  6. Cumulative Percentage of Abnormal Involuntary Movement Scale (AIMS) Responders by Response Level (Percentage Improvement From Baseline) at Week 12

    Response level represents the % improvement in AIMS from baseline. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). Patients with a missing AIMS score were considered to be AIMS nonresponders.

    Time frame: Day 0 (Baseline), Week 12

  7. Change in Locally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis

    This outcome is similar to the primary outcome except that AIMS was read locally. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. This outcome reports the local reading of AIMS data. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point (weeks 2, 4, 6, 9, and 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate.

    Time frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12

07

Results

Posted Mar 20, 2018

Participant flow

Participant flow — Overall Study
MilestoneSD-809Placebo
Started5859
Safety and itt populations5859
Modified itt population5657
Maintenance period5354
Completed5252
Not completed67
Withdrew: Protocol violation02
Withdrew: Noncompliance10
Withdrew: Adverse event12
Withdrew: Withdrawal by subject32
Withdrew: Lost to follow-up11

Outcome measures

PrimaryChange in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis

AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point, treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. An unstructured covariance model was used.

Time frame:
Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis
units on a scaleSD-809Placebo
Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) Analysis-3.0 ± 0.45-1.6 ± 0.46
Statistical analysis
  • SD-809 vs Placebo · unstructured covariance · p = 0.0188 (5% level of significance (2-sided)) · Lsm difference: -1.4 · 95% CI -2.6 to -0.2
SecondaryPercentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)

The CGIC is a single-item questionnaire that asks the investigator to assess a patient's TD symptoms at specific visits after initiating therapy. The CGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)
percentage of participantsSD-809Placebo
Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Clinical Global Impression of Change (CGIC)48.240.4
Statistical analysis
  • SD-809 vs Placebo · Pearson's chi-square test · p = 0.4001 (5% level of significance (2-sided)) · Differences in %: 7.9 · 95% CI -10.2 to 25.2
SecondaryPercentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)

The PGIC is a single-item questionnaire that asks the patient to assess their TD symptoms at specific visits after initiating therapy. The PGIC uses a 7 point Likert Scale, ranging from very much worse (-3) to very much improved (+3), to assess overall response to therapy. A treatment success was defined as "much improved" or "very much improved" at the week 12 visit. Patients whose status at week 12 was not known, as well as patients who were not "much improved" or "very much improved" at the week 12 visit, were considered treatment failures.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)
percentage of participantsSD-809Placebo
Percentage of Patients Who Are a Treatment Success at Week 12 as Assessed by the Patient Global Impression of Change (PGIC)42.929.8
SecondaryChange From Baseline to Week 12 in the Modified Craniocervical Dystonia Questionnaire (CDQ-24)

The CDQ-24 is a disease-specific quality of life questionnaire developed for use in patients with craniocervical dystonia, including both cervical dystonia (CD) and blepharospasm (BPS). The CDQ 24 was modified such that the questions focus more directly on the impact of TD (as opposed to CD/BPS) on quality of life. The following domains are evaluated in the CDQ-24: stigma, emotional well-being, pain, activities of daily living, and social/family life. Each of the 24 questions were rated by patients on a scale of 0=no impairment to 4=severest impairment for a total scale of 0 (no impairment) to 96 (severe impairment). Negative change from baseline scores indicate improvement.

Time frame:
Day 0 (Baseline), Week 12 with last observation carried forward
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in the Modified Craniocervical Dystonia Questionnaire (CDQ-24)
units on a scaleSD-809Placebo
Change From Baseline to Week 12 in the Modified Craniocervical Dystonia Questionnaire (CDQ-24)-11.1 ± 2.14-8.3 ± 2.31
SecondaryParticipants With Adverse Events for the Overall Treatment Period

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator and includes possibly, probably and definitely related categories. Serious AEs (SAE) include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Time frame:
Day 1 to Week 12
Reported as:
Count of participants · Participants
Participants With Adverse Events for the Overall Treatment Period
ParticipantsSD-809Placebo
Overall Treatment Period: any AE4136
Overall Treatment Period: SAE35
Overall Treatment Period: Severe AE33
Overall Treatment Period: treatment-related AE2821
Overall Treatment Period: Deaths00
SecondaryPercentage Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis

AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative percent change from baseline score indicates improvement. The MMRM model includes fixed effects for treatment, time point (weeks 2, 4, 6, 9, 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate. Patient is a random effect.

Time frame:
Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12
Reported as:
Least squares mean · percentage change
Percentage Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis
percentage changeSD-809Placebo
Percentage Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis-26.7 ± 6.06-15.5 ± 6.26
SecondaryCumulative Percentage of Abnormal Involuntary Movement Scale (AIMS) Responders by Response Level (Percentage Improvement From Baseline) at Week 12

Response level represents the % improvement in AIMS from baseline. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. AIMS was digitally video recorded using a standard protocol and independently reviewed by blinded central raters who were experts in movement disorders. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). Patients with a missing AIMS score were considered to be AIMS nonresponders.

Time frame:
Day 0 (Baseline), Week 12
Reported as:
Number · percentage of participants
Cumulative Percentage of Abnormal Involuntary Movement Scale (AIMS) Responders by Response Level (Percentage Improvement From Baseline) at Week 12
percentage of participantsSD-809Placebo
>=10%69.642.1
>=20%50.029.8
>=30%46.424.6
>=40%32.122.8
>=50%23.217.5
>=60%19.68.8
>=70%10.71.8
>=80%8.91.8
>=90%3.61.8
SecondaryChange in Locally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis

This outcome is similar to the primary outcome except that AIMS was read locally. AIMS is an assessment tool used to detect and follow the severity of TD over time. The AIMS is composed of 12 clinician-administered and scored items. This outcome reports the local reading of AIMS data. This outcome sums items 1 through 7 which cover orofacial movements, and extremity and truncal dyskinesia. Severity ratings were from 0 (none) to 4 (severe) for a total scale of 0 (no orofacial, truncal, and extremity dyskinesia) to 28 (severe orofacial, truncal, and extremity dyskinesia). A negative change from baseline score indicates improvement. A MMRM analysis with change from baseline in AIMS score as dependent variable was used. The model included fixed effects for treatment, time point (weeks 2, 4, 6, 9, and 12), treatment-by-time point interaction, DRA status, and baseline AIMS as a covariate.

Time frame:
Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12
Reported as:
Least squares mean · units on a scale
Change in Locally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis
units on a scaleSD-809Placebo
Change in Locally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using MMRM Analysis-4.9 ± 0.64-3.7 ± 0.65

Adverse events

Collected over Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SD-8090/58 (0%)3/58 (5.2%)24/58 (41.4%)
Placebo0/59 (0%)5/59 (8.5%)26/59 (44.1%)
Most frequent serious events
Most frequent serious events
EventSD-809Placebo
PneumoniaInfections and infestations1/581/59
SchizophreniaPsychiatric disorders1/580/59
ManiaPsychiatric disorders1/580/59
Abscess jawInfections and infestations0/581/59
OverdoseInjury, poisoning and procedural complications0/581/59
Jaw fractureInjury, poisoning and procedural complications0/581/59
Laryngeal hypertrophyRespiratory, thoracic and mediastinal disorders0/581/59
Most frequent other events
Showing 10 of 12
Most frequent other events
EventSD-809Placebo
SomnolenceNervous system disorders8/586/59
Dry mouthGastrointestinal disorders2/586/59
HeadacheNervous system disorders3/586/59
FatigueGeneral disorders4/585/59
InsomniaPsychiatric disorders4/581/59
AnxietyPsychiatric disorders2/584/59
DiarrhoeaGastrointestinal disorders3/583/59
AkathisiaNervous system disorders3/580/59
VomitingGastrointestinal disorders1/583/59
Upper respiratory tract infectionInfections and infestations2/583/59

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)SD-809PlaceboTotal
Mean55.9 ± 9.8253.3 ± 10.6454.6 ± 10.28
Sex: Female, Male
Sex: Female, Male(Participants)SD-809PlaceboTotal
Female293261
Male292756
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SD-809PlaceboTotal
Hispanic or Latino41115
Not Hispanic or Latino5347100
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SD-809PlaceboTotal
American Indian or Alaska Native000
Asian213
Native Hawaiian or Other Pacific Islander000
Black or African American191433
White374481
More than one race000
Unknown or Not Reported000
Education Level
Education Level(Participants)SD-809PlaceboTotal
=12 years or fewer of formal education303060
>12 years of formal education282957
Weight
Weight(kg)SD-809PlaceboTotal
Mean86.94 ± 24.08184.95 ± 20.97585.94 ± 22.493
Height
Height(cm)SD-809PlaceboTotal
Mean169.23 ± 11.462169.72 ± 10.098169.48 ± 10.752
Body Mass Index
Body Mass Index(kg/m^2)SD-809PlaceboTotal
Mean30.35 ± 7.92629.45 ± 6.95829.89 ± 7.435

4 further baseline measures are reported on the registry.

08

Study locations

41 sites
  • Tuscaloosa, Alabama, United States
  • Anaheim, California, United States
  • Glendale, California, United States
  • Oceanside, California, United States
  • Orange, California, United States
  • San Bernardino, California, United States
  • San Diego, California, United States
  • Denver, Colorado, United States
  • New Haven, Connecticut, United States
  • Stamford, Connecticut, United States
  • Washington, District of Columbia, United States
  • Boca Raton, Florida, United States
  • Gainesville, Florida, United States
  • Lake City, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Port Charlotte, Florida, United States
  • Chicago, Illinois, United States
  • Baltimore, Maryland, United States
  • Minneapolis, Minnesota, United States
  • Kansas City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Albuquerque, New Mexico, United States
  • Asheville, North Carolina, United States
  • Durham, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Memphis, Tennessee, United States
  • Fort Worth, Texas, United States
  • Salt Lake City, Utah, United States
  • Prague, Czechia
  • Gdansk, Poland
  • Katowice, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Lublin, Poland
  • Torun, Poland
  • Hronovce, Slovakia
  • Roznava, Slovakia
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in May 2015, 11 months.

Results were first posted in Mar 2018, 2 years 10 months after primary completion. A results delay was requested in Apr 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2014
First posted
Jul 21, 2014
StartActual
Jun 2014
Primary completionActual
May 2015
CompletionActual
May 2015
Results delay requested
Apr 24, 2017
Results first posted
Mar 20, 2018
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02195700
Responsible party
Sponsor
First posted
Jul 21, 2014
Start date
Jun 2014
Primary completion
May 2015
Completion
May 2015
Results posted
Mar 20, 2018
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, M.D.
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deutetrabenazine

Start the discussion